Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: A comparison between healthy subjects and type 1 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 6, 2004, Pages 2957-2962

  Ferretti, G ^a   Bacchetti, T ^a   Busni, D ^b   Rabini, R A ^c   Curatola, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Azienda Ospedaliera Umberto I   (Italy)

^c Ist Naz Riposo e Cura Per Anziani   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; CELL PROTECTION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; INCUBATION TIME; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; ARYLDIALKYLPHOSPHATASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ERYTHROCYTE MEMBRANE; FEMALE; HUMANS; LIPID PEROXIDATION; LIPID PEROXIDES; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 2942640231     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031897     Document Type: Conference Paper

References (40)

1. Assmann G, Nofer J-R 2003 Atheroprotective effects of high density lipoproteins. Annu Rev Med 54:321-341
2. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A 2002 HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161:1-16
3. Parthasarathy S, Barnett J, Fong L-G 1990 High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta 1044:275-283
4. Klimov A-N, Kozhevnikova K-A, Kuzmin A-A, Kuznetsov A-S, Belova E-V 2001 On the ability of high density lipoproteins to remove phospholipid peroxidation products from erythrocyte membranes. Biochemistry Mosc 66: 300-304
5. ++-induced oxidation of astrocytes. J Trace Elem Med Biol 17:25-30
6. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M 1995 Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882-2891
7. Mackness MI, Arrol S, Abbott C, Durrington PN 1993 Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135
8. Durrington PN, Mackness B, Mackness MI 2001 Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480
9. Jaouad L, Milochevitch C, Khalil A 2003 PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 37:77-83
10. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B 1999 Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892-904
11. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G 2001 Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38:163-169
12. Ferretti G, Bacchetti T, Marotti E, Curatola G 2003 Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 52:146-151
13. Baynes JW 1991 Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412
14. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP 1995 Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054-1058
15. Beaudeux JL, Guillausseau PJ, Peynet J, Flourie F, Assayag M, Tielmans D, Warnet A, Rousselet F 1995 Enhanced susceptibility of low density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Clin Chim Acta 239:131-141
16. Rabini RA, Fumelli P, Galassi R, Dousset N, Taus M, Ferretti G, Mazzanti L, Curatola G, Solera ML, Valdiguie P 1994 Increased susceptibility to lipid oxidation of low density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism 43:1470-1474
17. Santini SA, Marra G, Giardina B, Cotroneo P, Mordente A, Martorana GE, Manto A, Ghirlanda G 1997 Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes 46:1853-1858
18. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN 1991 Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86:193-199
19. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI 2002 Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 32:259-264
20. Abbott CA, Mackness ML Kumar S, Boulton AJ, Durrington PN 1995 Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812-1818
21. Valabhji J, McColl A-J, Schachter M, Dhanjil S, Richmond W, Elkeles RS 2001 High density lipoprotein composition and paraoxonase activity in type 1 diabetes. Clin Sci (Lond) 101:659-670
22. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW 1999 Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19:2226-2233
23. Fievet C, Theret N, Shojaee N, Duchateau P, Castro G, Ailhaud G, Drouin P, Fruchart JC 1992 Apolipoprotein A-I-containing particles and reverse cholesterol transport in IDDM. Diabetes 41:81-85
24. Guo L, Ogamo A, Ou Z, Shinozuka T, Nakagawa Y 1995 Preferential formation of the hydroperoxide of linoleic acid in choline glycerophospholipids in human erythrocytes membrane during peroxidation with an azo-initiator. Free Radic Biol Med 18:1003-1012
25. Nishio E, Watanabe Y 1997 Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 236:289-293
26. Feingold KR, Memon RA, Moser AH, Grunfeld C 1998 Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307-315
27. Chung BH, Segrest JP, Ray MJ, Brunzell JD, Hokanson JE, Krauss RM, Beaudrie K, Cone JT 1986 Single vertical spin density gradient ultracentrifugation. Methods Enzymol 128:181-209
28. Lowry OH, Rosebrough NJ, Farr AL, Randall PJ 1951 Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
29. Burton GW, Ingold KU, Thompson KE 1981 An improved procedure for the isolation of ghost membranes from human red blood cells. Lipids 16:946
30. Ferretti G, Marchionni C, Bacchetti T, Galeazzi T, Curatola G 2003 Effect of aluminium on lipid peroxidation of human high density lipoproteins. Free Radic Res 37:515-521
31. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Mackness M 1992 Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. Arterioscler Thromb 12:920-928
32. Hayashibe H, Asayama K, Nakane T, Kobayashi K, Amemiya S, Nakazawa S 1999 Decreased activity of plasma cholesteryl ester transfer protein in children and adolescents with insulin-dependent diabetes mellitus. Acta Paediatr 88:1067-1070
33. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O'Connor J, Van Tol A 2002 Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 51:3300-3305
34. Weight MJ, Coetzee HS, Smuts CM, Marais MP, Maritz JS, Hough FS, Benade AJ, Taljaard JJ 1993 Lecithin:cholesterol acyltransferase activity and high density lipoprotein subfraction composition in type 1 diabetic patients with improving metabolic control. Acta Diabetol 30:159-165
35. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN 1999 Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19:2214-2225
36. Ferretti G, Taus M, Dousset N, Solera ML, Valdiguie P, Curatola G 1993 Physico-chemical properties of copper-oxidized high density lipoprotein: a fluorescence study. Biochem Mol Biol Int 30:713-719
37. Salmon S, Maziere C, Auclair M, Theron L, Santus R, Maziere JC 1992 Malondialdehyde modification and copper-induced autooxidation of high density lipoprotein decrease cholesterol efflux from human cultured fibroblasts. Biochim Biophys Acta 1125:230-235
38. Huuskonen J, Olkkonen VM, Jauhiainen M, Sareneva T, Somerharju P, Ehnholm C 1998 Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer. Biochim Biophys Acta 1391:181-192
39. Cavallero E, Brites F, Delfly B, Nicolaiew N, Decossin C, De Geitere C, Fruchart JC, Wikinski R, Jacotot B, Castro G 1995 Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 15:2130-2135
40. Graham A, Hassall DG, Rafique S, Owen JS 1997 Evidence for a paraoxonase-independent inhibition of low density lipoprotein oxidation by high density lipoprotein. Atherosclerosis 135:193-204